📈 Revenue History (16 Quarters)
🧮 SPRO Revenue Breakdown
Understanding Revenue
Revenue, also called sales or the "top line," represents the total income a company generates from its business activities before any costs are deducted. For SPRO, the trailing twelve month revenue is $18.3M.
Why Revenue Matters
Revenue is the foundation of all financial analysis. A company cannot have sustainable profits without revenue, and revenue growth often drives stock price appreciation. However, revenue alone doesn't tell the full story - it must be analyzed alongside profitability metrics.
SPRO's revenue growth rate of 24.07% (based on log-linear regression of 16 quarters) indicates strong growth, typical of high-growth companies.
Revenue vs Profitability Metrics
Free Cash Flow: $0 →
The cash remaining after capital expenditures. High revenue with negative FCF may indicate heavy reinvestment or poor cash conversion.
Owner Earnings: N/A →
Buffett's metric for true cash generation. Compares revenue's conversion to actual owner value.
Earnings Per Share: $0.14 →
Net income per share. The bottom line result of all revenue after costs, taxes, and interest.
Net Income: $7.4M
What remains after all expenses. Net margin shows what percentage of revenue becomes profit.
Price/Sales Ratio Analysis
SPRO's P/S ratio of 3.9x means investors pay $3.87 for every $1 of annual revenue. A P/S between 3-10 suggests investors expect continued growth and margin expansion.
Gross Margin: Revenue Quality
Gross margin of N/A shows how much of SPRO's revenue remains after direct costs.
Summary: SPRO Revenue Trend
SPERO THERAPEUTICS, INC. (SPRO) generated $18.3M in trailing twelve-month revenue, growing at 24.07% annually — significantly above the 20% threshold Zyberno associates with high-growth businesses. Gross margin: N/A. For complete financial analysis, view the full SPRO stock report on Zyberno.
Frequently Asked Questions
What is SPRO's current revenue?
SPERO THERAPEUTICS, INC.'s trailing twelve month (TTM) revenue is $18.3M, growing at 24.07% annually — significantly above the 20% threshold Zyberno associates with high-growth businesses.
Is SPRO's revenue growing?
SPERO THERAPEUTICS, INC. (SPRO) generated $18.3M in trailing twelve-month revenue, growing at 24.07% annually — significantly above the 20% threshold Zyberno associates with high-growth businesses. Gross margin: N/A.
What is SPRO's gross margin?
SPRO's gross margin is N/A.
What is SPRO's Price/Sales ratio?
SPRO's P/S ratio is 3.9x, meaning the market values the company at 3.9 times its annual revenue.
How does revenue differ from profit?
Revenue is the total income before any expenses, while profit (net income) is what remains after all costs. SPRO's revenue is $18.3M with a net income of $7.4M, showing a net profit margin of 40.4%.
📊 Full SPRO Stock Report →
See SPRO's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.
💵 SPRO Free Cash Flow →
Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.
💰 SPRO Owner Earnings →
Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.
📈 SPRO Earnings Per Share →
Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.
🎯 SPRO Earnings Surprise (SUE) →
See whether SPRO is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.
📊 SPRO Revenue →
Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.
💰 SPRO Net Income →
Analyze the bottom-line profit, P/E ratio, and net profit margin trends.
🔶 SPRO Operating Income →
Analyze EBIT, operating margin, and core business profitability before interest and taxes.
💜 SPRO Gross Profit →
Analyze gross margin, pricing power, and profitability before operating expenses.